Myriad Genetics Inc (MYGN)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
CEO:
Paul J. Diaz
Employees:
2,400
320 WAKARA WAY, SALT LAKE CITY, UT 84108
801-584-3600

Myriad Genetics, Inc. develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers.

Data derived from most recent annual or quarterly report
Market Cap 1.617 Billion Shares Outstanding81.034 Million Avg 30-day Volume 564.046 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.2
Price to Revenue2.328 Debt to Equity0.0 EBITDA-78.6 Million
Price to Book Value1.6799 Operating Margin-19.8821 Enterprise Value1.281 Billion
Current Ratio2.729 EPS Growth0.541 Quick Ratio2.288
1 Yr BETA 1.4661 52-week High/Low 28.18 / 13.92 Profit Margin-11.6873
Operating Cash Flow Growth-207.1076 Altman Z-Score3.1636 Free Cash Flow to Firm -194.55 Million
Earnings Report2023-02-23
View SEC Filings from MYGN instead.

View recent insider trading info

Myriad Genetics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding MYGN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MYGN

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-01-23 by RIGGSBEE RICHARD BRYAN
  • 4: filed on 2023-01-19 by RIGGSBEE RICHARD BRYAN
  • 4: filed on 2023-01-04 by MUZZEY DALE
  • 4: filed on 2023-01-04 by LAMBERT NICOLE
  • 4: filed on 2022-12-28 by RIGGSBEE RICHARD BRYAN
  • 4: filed on 2022-11-01 by BISARO PAUL
  • 3: filed on 2022-11-01 by BISARO PAUL
  • 4: filed on 2022-10-19 by WONG PAMELA
  • 4: filed on 2022-10-11 by MUZZEY DALE
  • 4: filed on 2022-10-11 by RIGGSBEE RICHARD BRYAN

    • Events (8k)

  • 8-K: filed on 2022-11-01:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-27:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-30:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-06-02:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-01:
    Item 8.01: Other Events
  • 8-K: filed on 2022-02-24:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-09:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    30 Thousand total shares from 3 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    RIGGSBEE RICHARD BRYAN CHIEF FINANCIAL OFFICER

    • Officer
    		 364,107 2023-01-20 9

    LAMBERT NICOLE CHIEF OPERATING OFFICER

    • Officer
    		 228,404 2023-01-01 7

    MUZZEY DALE CHIEF SCIENTIFIC OFFICER

    • Officer
    		 42,712 2023-01-01 5

    BISARO PAUL

    • Director
    		 0 2022-10-31 2

    WONG PAMELA CHIEF LEGAL OFFICER

    • Officer
    		 51,860 2022-10-18 3

    VERRATTI MARK CHIEF COMMERCIAL OFFICER

    • Officer
    		 228,022 2022-10-09 8

    HART JAYNE B. CHIEF PEOPLE OFFICER

    • Officer
    		 172,561 2022-10-09 8

    HAAS KEVIN RICHARD CHIEF TECHNOLOGY OFFICER

    • Officer
    		 85,295 2022-10-09 6

    MUNK NATALIE CHIEF ACCOUNTING OFFICER

    • Officer
    		 25,186 2022-08-25 2

    DIAZ PAUL J PRESIDENT AND CEO

    • Officer
    • Director
    		 1,087,079 2022-08-13 4

    LANGER DENNIS

    • Director
    		 136,802 2022-06-30 2

    SPIEGELMAN DANIEL K

    • Director
    		 33,980 2022-06-06 2

    DREISMANN HEINRICH

    • Director
    		 100,802 2022-06-02 1

    PHANSTIEL S. LOUISE

    • Director
    		 129,921 2022-06-02 1

    REITAN COLLEEN F

    • Director
    		 57,699 2022-06-02 1

    SKOVRONSKY DANIEL

    • Director
    		 55,164 2022-06-02 1

    NEWCOMER LEE NISLEY

    • Director
    		 57,699 2022-06-02 1

    KUMAR RASHMI

    • Director
    		 54,046 2022-06-02 1

    SANTA ERIC FORMER CHIEF GROWTH OFFICER

    • Officer
    		 56,734 2022-04-26 4

    ANCONA MARGARET SEE REMARKS

    • Officer
    		 37,160 2022-03-22 2

    LANCHBURY JERRY S SEE REMARKS

    • Officer
    		 264,324 2022-01-14 0

    DREISMANN HEINRICH

    • Director
    		 83,527 2021-06-03 0

    PARKINSON PAUL FMR EVP STRATEGY & INNOVATION

    • Officer
    		 No longer subject to file 2021-05-14 0

    JACKSON BENJAMIN FORMER E.V.P., GENERAL COUNSEL

    • Officer
    		 No longer subject to file 2021-04-12 0

    FORD ALEXANDER CHIEF OPERATING OFFICER

    • Officer
    		 169,040 2020-09-30 0

    GILBERT WALTER PHD

    • Director
    		 54,150 2019-12-13 0

    BEST LAWRENCE C

    • Director
    		 60,790 2019-12-05 0

    HENDERSON JOHN T

    • Director
    		 78,090 2019-12-05 0

    CAPONE MARK CHRISTOPHER PRESIDENT & C.E.O.

    • Officer
    		 522,216 2019-09-30 0

    KING GARY A. EXEC. VP INTERNATIONAL OPS

    • Officer
    		 148,397 2019-09-30 0

    MCDADE RALPH L PRESIDENT MYRIAD RBM, INC.

    • Officer
    		 142,095 2019-09-30 0

    TOBIN BERNARD PRESIDENT CRESCENDO BIOSCIENCE

    • Officer
    		 160,636 2019-09-30 0

    MARSH RICHARD M E.V.P., GENERAL COUNSEL

    • Officer
    		 144,174 2018-09-30 0

    SANDERS WALTER LLOYD PRESIDENT MYRIAD ONCOLOGY

    • Officer
    		 36,195 2018-09-30 0

    WENSTRUP RICHARD CHIEF MEDICAL OFFICER

    • Officer
    		 50,207 2016-09-30 0

    DROSOS VIRGINIA PRESIDENT ASSUREX HEALTH

    • Officer
    		 50,000 2016-09-14 0

    MELDRUM PETER D PRESIDENT & C.E.O.

    • Officer
    • Director
    		 10,869 2014-11-05 0

    EVANS JAMES S CHIEF FINANCIAL OFFICER

    • Officer
    		 48,128 2014-09-30 0

    HARRISON ROBERT GARDNER CHIEF INFORMATION OFFICER

    • Officer
    		 25,844 2014-09-17 0

    ROGERS RONALD S. EXEC VP CORP COMMUNICATIONS

    • Officer
    		 16,000 2014-09-17 0

    HAGSTROM WILLIAM A PRES. CRESCENDO BIOSCIENCE

    • Officer
    		 0 2014-02-28 0

    BENSON T CRAIG PRESIDENT, MYRIAD RBM

    • Officer
    		 0 2013-09-17 0

    WILSON LINDA S

    • Director
    		 2,500 2010-01-07 0

    SKOLNICK MARK H CHIEF SCIENTIFIC OFFICER

    • Officer
    • Director
    		 549,001 2009-11-04 0

    BELLE GERALD P.

    • Director
    		 0 2009-11-04 0

    CRITCHFIELD GREGORY C PRESIDENT MYRIAD GENETIC LABS

    • Officer
    		 0 2009-09-15 0

    HOBDEN ADRIAN N PRES. MYRIAD PHARMACEUTICALS

    • Officer
    		 234,071 2009-06-08 0

    LASLIE W WAYNE CHIEF OPERATING OFFICER, MPI

    • Officer
    		 44,260 2009-05-08 0

    ATTIYEH ROBERT S

    • Director
    		 0 2008-11-13 0

    HOCKETT WILLIAM A III V. P. OF CORP COMMUNICATIONS

    • Officer
    		 0 2008-09-10 0

    HAYES ARTHUR HULL JR

    • Director
    		 15,000 2007-11-15 0

    MOYES JAY M CHIEF FINANCIAL OFFICER

    • Officer
    		 25,282 2007-10-15 0

    SIMON S GEORGE V.P. BUSINESS DEVELOPMENT

    • Officer
    		 21,410 2007-01-16 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    RIGGSBEE RICHARD BRYAN - Officer CHIEF FINANCIAL OFFICER

    		2023-01-23 16:14:05 -0500 2023-01-20 S 9,400 $20.04 d 364,107 direct yes -2.1936 -5.9609 0.0 1 -8.1545 5

    RIGGSBEE RICHARD BRYAN - Officer CHIEF FINANCIAL OFFICER

    		2023-01-19 17:56:22 -0500 2023-01-18 S 600 $20.01 d 373,507 direct yes 5.2088 0.0983 5.2088 2 -2.6536 5

    LAMBERT NICOLE - Officer CHIEF OPERATING OFFICER

    		2023-01-04 18:07:19 -0500 2023-01-01 F 853 $14.51 d 228,404 direct 2.2458 17.1553 17.1553 6 0.0 1

    MUZZEY DALE - Officer CHIEF SCIENTIFIC OFFICER

    		2023-01-04 18:09:17 -0500 2023-01-01 F 302 $14.51 d 42,712 direct 2.2458 17.1553 17.1553 6 0.0 1

    RIGGSBEE RICHARD BRYAN - Officer CHIEF FINANCIAL OFFICER

    		2022-12-28 16:05:33 -0500 2022-12-27 S 20,000 $15.15 d 374,107 direct yes -0.6164 12.2603 12.2603 6 -0.6164 2

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    MYRIAD GENETICS INC MYGN 2023-02-03 22:15:03 UTC 4.32 0.25 3500000
    MYRIAD GENETICS INC MYGN 2023-02-03 21:45:03 UTC 4.32 0.25 3500000
    MYRIAD GENETICS INC MYGN 2023-02-03 21:15:03 UTC 4.32 0.25 3500000
    MYRIAD GENETICS INC MYGN 2023-02-03 20:45:06 UTC 4.32 0.25 3500000
    MYRIAD GENETICS INC MYGN 2023-02-03 20:15:04 UTC 4.32 0.25 3500000
    MYRIAD GENETICS INC MYGN 2023-02-03 19:45:03 UTC 4.32 0.25 3500000
    MYRIAD GENETICS INC MYGN 2023-02-03 19:15:04 UTC 4.32 0.25 3500000
    MYRIAD GENETICS INC MYGN 2023-02-03 18:45:03 UTC 4.2992 0.2708 3500000
    MYRIAD GENETICS INC MYGN 2023-02-03 18:15:03 UTC 4.2992 0.2708 3500000
    MYRIAD GENETICS INC MYGN 2023-02-03 17:45:03 UTC 4.2992 0.2708 3500000
    MYRIAD GENETICS INC MYGN 2023-02-03 17:15:04 UTC 4.2992 0.2708 3500000
    MYRIAD GENETICS INC MYGN 2023-02-03 16:45:04 UTC 4.1619 0.4081 3500000
    MYRIAD GENETICS INC MYGN 2023-02-03 16:15:03 UTC 4.1619 0.4081 3500000
    MYRIAD GENETICS INC MYGN 2023-02-03 15:45:03 UTC 4.1619 0.4081 3500000
    MYRIAD GENETICS INC MYGN 2023-02-03 15:15:03 UTC 4.1619 0.4081 3500000
    MYRIAD GENETICS INC MYGN 2023-02-03 14:45:04 UTC 3.9119 0.4081 3500000
    MYRIAD GENETICS INC MYGN 2023-02-03 14:15:04 UTC 3.9119 0.4081 3500000
    MYRIAD GENETICS INC MYGN 2023-02-03 13:45:03 UTC 3.9119 0.4081 3500000
    MYRIAD GENETICS INC MYGN 2023-02-03 13:15:03 UTC 3.9119 0.4081 3500000
    MYRIAD GENETICS INC MYGN 2023-02-03 12:45:03 UTC 3.9119 0.4081 3100000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Enhanced Index Plus Fund MYGN -561.0 shares, $-8027.91 2020-03-31 N-PORT
    FundVantage Trust- Gotham Defensive Long Fund MYGN -311.0 shares, $-4450.41 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund MYGN -526.0 shares, $-7527.06 2020-03-31 N-PORT
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund MYGN -5200.0 shares, $-99216.0 2022-09-30 N-PORT
    Columbia Funds Series Trust I- Multi-Manager Directional Alternative Strategies Fund MYGN -6474.0 shares, $-134270.76 2022-10-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments